Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

BPC-157 Research Guide | Complete Overview | Palmetto Peptides

What Is BPC-157? A Complete Research Introduction Last Updated: July 8, 2026 | Reading Time: Approximately 8 minutes | Author: Palmetto Peptides Research Team Quick Answer BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a pr

By Recovery & Performance Peptides Editorial Team

What Is BPC-157? A Complete Research Introduction

Last Updated: July 8, 2026 | Reading Time: Approximately 8 minutes | Author: Palmetto Peptides Research Team

Quick Answer

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. Comprising 15 amino acids (sequence: GEPPPGKPADDAGLV), it has been the subject of extensive preclinical research since the early 1990s. Animal model studies have examined its effects across gastrointestinal tissue, musculoskeletal repair, neurological protection, and vascular signaling — making it one of the most broadly studied research peptides in the preclinical literature.

Research Notice: This article covers research on BPC-157 research peptide — available from Palmetto Peptides for laboratory use only.

Research Use Only Disclaimer: All peptides listed on this page are sold exclusively for in vitro and legitimate laboratory research purposes. They are not intended for human consumption, veterinary use, or any clinical application. The information in this article is for scientific and educational reference only and does not constitute medical advice. All research use must comply with applicable federal, state, and institutional regulations. Palmetto Peptides complies fully with all applicable FDA guidelines.

Research Use Only: BPC-157 is not approved by the FDA for human consumption, therapeutic use, or veterinary applications. All research referenced in this article was conducted in animal models or in vitro systems. This compound is sold by Palmetto Peptides exclusively for licensed laboratory research.

What Is BPC-157?

BPC-157 is a synthetic peptide fragment derived from Body Protection Compound, a naturally occurring protein isolated from human gastric juice. The compound consists of 15 amino acids in the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV), giving it a molecular weight of approximately 1419.5 Da.

Unlike many endogenous peptides, BPC-157 demonstrates unusual stability in the presence of gastric acid — the environment from which it was originally isolated. This acid resistance, combined with its relatively small size, has made it a practical and consistent subject for preclinical study across multiple delivery routes and tissue models.

The compound was first characterized by Dr. Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s. Since then, it has accumulated one of the largest bodies of published preclinical literature of any synthetic peptide, with hundreds of peer-reviewed animal studies spanning gastroenterology, orthopedics, neurology, and vascular biology.

Molecular Properties

Molecular formula: C₆₂H₉₈N₁₆O₂₂

Molecular weight: 1419.5 Da

Sequence: GEPPPGKPADDAGLV (15 amino acids)

Origin: Fragment of human gastric juice BPC protein

Form (research use): Lyophilized powder; requires reconstitution with bacteriostatic water

Stability: Resistant to gastric acid hydrolysis; stable under standard laboratory storage conditions

Research purity standard: ≥98% (HPLC verified)

Discovery and Research History

BPC-157 was initially isolated as part of research into the cytoprotective properties of gastric juice. The stomach produces a range of protective factors that shield its own mucosal lining from the corrosive acid environment — and researchers identified BPC as one of these factors. The 157-amino acid fragment (hence "BPC-157") proved to be the most stable and biologically active portion, making it the focus of subsequent research.

Early studies from the Zagreb group focused primarily on GI applications, examining healing effects in models of stomach ulcers, inflammatory bowel disease, and esophageal damage. As the compound's mechanisms were characterized — particularly its interactions with growth hormone receptors, nitric oxide (NO) synthesis, and vascular endothelial growth factor (VEGF) — research expanded substantially into other tissue systems.

By the 2010s, BPC-157 had become one of the most-published synthetic peptides in the preclinical literature, with studies examining its effects in virtually every major organ system in rodent models.

Primary Research Areas

Published preclinical research has investigated BPC-157 across four major domains:

Gastrointestinal Research: The original and most extensively studied application. Animal models have examined BPC-157's effects on gastric mucosal healing, inflammatory bowel markers, fistula closure, short bowel syndrome, and esophageal injury. Researchers have noted its resistance to gastric acid as particularly relevant for GI tissue-system studies.

Musculoskeletal Research: A large body of rodent studies has examined tendon, ligament, bone, and muscle injury models. BPC-157 is frequently studied alongside TB-500 in this space — the two peptides appear to act through complementary rather than overlapping mechanisms, making them natural subjects for combination research.

Neurological Research: More recent publications have examined BPC-157 in CNS injury models, including peripheral nerve damage, traumatic brain injury, and dopaminergic system protection. Studies have examined potential interactions with serotonin, dopamine, and GABA signaling pathways in rodent models.

Vascular Research: BPC-157 has been studied in the context of angiogenesis and wound closure. Its interaction with nitric oxide pathways and VEGF signaling has been a consistent focus, with researchers examining effects on blood vessel formation in wound healing models.

Mechanisms Under Investigation

Several molecular mechanisms have been identified and studied in the preclinical BPC-157 literature:

Growth hormone receptor interaction: BPC-157 appears to interact with GH receptor signaling pathways, which may contribute to its tissue repair effects in animal models.

Nitric oxide (NO) modulation: Studies have examined BPC-157's effects on both nitric oxide synthase (NOS) expression and NO availability in tissue repair contexts.

VEGF pathway interaction: BPC-157 has been shown to influence VEGF expression in wound healing and angiogenesis models, potentially explaining some of its observed effects on vascular tissue.

Tendon fibroblast activity: In vitro studies have examined BPC-157's effects on tenocyte proliferation and collagen synthesis.

BPC-157 vs Other Research Peptides

BPC-157 occupies a unique niche in research peptide biology: it is one of the few synthetic peptides with a substantial body of published in vivo animal data across multiple organ systems. Most peptides are studied within a narrow application domain. BPC-157's breadth of study — and the consistency of observations across independent research groups — has made it a reference compound in tissue repair research.

Its most frequent research partner is TB-500 (the active region of Thymosin Beta-4). Where BPC-157 acts primarily through GH receptor and NO signaling for localized effects, TB-500 operates through actin polymerization and cell migration for more systemic tissue remodeling. The combination — often called the Wolverine Stack — covers complementary repair pathways and has been widely studied in musculoskeletal models.

Research Grade Quality Standards

For laboratory use, BPC-157 should meet the following specifications:

Purity ≥98% verified by HPLC analysis

Batch-specific Certificate of Analysis (COA) from ISO-accredited laboratory

Lyophilized powder form (not pre-dissolved)

Proper cold-chain handling during shipping

Clear labeling with lot number, purity, and expiration

Third-party testing by an independent, ISO-accredited laboratory is the gold standard. Reputable suppliers provide batch-specific COAs — not generic or copy-pasted certificates.

Sourcing BPC-157 for Research

Research-grade BPC-157 is available as lyophilized powder from qualified peptide suppliers. When evaluating suppliers, researchers should verify: purity claims backed by third-party HPLC data, proper cold-chain shipping, clear research-use-only labeling, and responsive technical support for laboratory questions.

Palmetto Peptides BPC-157 is available in 5mg and 10mg variants, with ≥98% purity verified by COA-backed batch testing. Also available as the BPC-157 + TB-500 Wolverine Stack for researchers studying combined tissue repair mechanisms.

Related Research

Palmetto Peptides Guide to the Research Peptide Stack BPC-157 & TB-500: The Wolverine Stack

What Is TB-500?

Third-Party Testing and Purity Standards for Research-Grade TB-500 and BPC-157

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosing Calculation Errors That Compromise Experimental Validity

Dose miscalculation represents the most preventable failure mode in BPC-157 research. The error stems from confusion between concentration (mg/mL), total vial content (mg), and volume per administration (mL). Standard research-grade BPC-157 arrives as 5mg lyophilised powder per vial. Reconstituting with 2mL bacteriostatic water produces 2.5mg/mL concentration. To administer 250mcg (0.25mg). A common research dose. Requires 0.1mL of solution. Researchers frequently miscalculate by confusing micrograms with milligrams: 250mcg is not 250mg. Drawing 0.25mL from a 2.5mg/mL solution delivers 625mcg. 2.5 times the intended dose. The calculation sequence must follow this order: (1) determine target dose in micrograms, (2) convert to milligrams by dividing by 1,000, (3) divide by concentration in mg/mL to find volume in mL. For 250mcg target dose from 2.5mg/mL solution: 250mcg ÷ 1,000 = 0.25mg. Then 0.25mg ÷ 2.5mg/mL = 0.1mL. Insulin syringes marked in units (1 unit = 0.01mL) require 10 units for 0.1mL. Concentration changes when researchers use different bacteriostatic water volumes. Reconstituting 5mg powder with 1mL water produces 5mg/mL concentration. The same 250mcg dose now requires only 0.05mL (5 units on insulin syringe). Using the previous 0.1mL volume would deliver double the intended dose. Every protocol change requires recalculation from first principles. Researchers establishing tissue repair protocols often reference our Muscle Building Recovery Bundle as a concentratio…
STORAGE

Storage Validation and Pre-Use Stability Testing

Peptide degradation between receipt and use is the third failure point research teams underestimate. BPC-157 is a linear peptide without disulfide bonds, making it relatively stable compared to cyclic peptides, but the four proline residues create conformational rigidity that accelerates aggregation at concentrations above 5mg/mL. Lyophilised powder should be stored at −20°C in a desiccator cabinet. Exposure to room temperature for more than 48 hours or humidity above 40% causes moisture absorption that triggers deamidation of the two asparagine residues and oxidation of the single methionine if present in modified sequences. Once reconstituted in bacteriostatic water or sterile saline, BPC-157 degrades via multiple pathways. Peptide bonds adjacent to proline residues are susceptible to hydrolysis at pH below 5.0 or above 8.0. Maintain reconstituted solutions at pH 6.0–7.4. Bacterial growth in reconstituted peptides stored at 4°C beyond 14 days introduces proteases that cleave the peptide even in bacteriostatic water containing 0.9% benzyl alcohol. The gold standard is reconstituting only the volume needed for one week of injections, storing at 2–8°C in amber glass vials, and running fresh HPLC analysis if the solution sits longer than 10 days. Freeze-thaw cycles are particularly destructive for BPC-157 because the peptide aggregates at the ice-water interface during freezing. A single freeze-thaw reduces monomer content by 8–12%; three cycles can drop it below 80%. If you m…
02

Question drills

Open a question for its connected answer.

01What If Baseline Cortisol Levels Aren't Measured Before Starting a BPC-157 Protocol?+

Without baseline cortisol data, you can't distinguish peptide effects from pre-existing HPA dysregulation. Subjects with elevated baseline cortisol will systematically underperform compared to those with normal adrenal function, creating apparent 'non-responders' who are actually cortisol-confounded responders. The solution: implement mandatory pre-treatment cortisol screening via morning serum draw or four-point salivary cortisol curve, then stratify randomization by cortisol tertiles to ensure balanced distribution across treatment arms.

SOURCE / realpeptides.co ↗
02What If the Study Timeline Exceeds Peptide Stability Limits?+

Prepare single-use aliquots immediately after reconstitution and store at −20°C in cryovials. Avoid repeated freeze-thaw by thawing only the day's required dose. For studies longer than 28 days, prepare fresh batches at day 28 rather than extending storage beyond stability limits. Verify peptide activity at study midpoint using a functional assay (gastric cytoprotection or cell migration assay) to confirm no degradation has occurred. HPLC or mass spectrometry analysis at week 2 and week 4 provides quantitative stability data.

SOURCE / realpeptides.co ↗
03What If a Male Research Subject Using BPC-157 Plans Conception?+

Current evidence suggests negligible risk from paternal peptide use. BPC-157 does not concentrate in seminal fluid at levels that would expose a developing embryo post-fertilization, and the peptide does not alter sperm DNA integrity in animal models. The biological concern with BPC-157 research pregnancy considerations centers on maternal-fetal transfer through placental circulation, not paternal gamete exposure. Standard recommendations advise completing peptide protocols before active conception attempts as a conservative measure.

SOURCE / realpeptides.co ↗
04What if my reconstituted BPC-157 vial's expiration date passes mid-study?+

Reconstituted BPC-157 in bacteriostatic water maintains stability for 28 days when refrigerated at 2–8°C. This is the industry standard, not a cautious estimate. If your study extends beyond 28 days from reconstitution, you must reconstitute a fresh vial from lyophilised stock and document the transition in your protocol. Do not extend use beyond 28 days based on visual inspection. Peptide degradation is not visible to the eye, and potency loss occurs before any observable change in solution clarity. Document the vial transition date, verify the new vial's batch matches or is cross-referenced in your chain-of-custody log, and annotate your administration records to show which subjects received doses from which vial. This prevents cross-vial variability from confounding your endpoint analysis.

SOURCE / realpeptides.co ↗
05What If the Research Protocol Requires Multiple Dosing Events from the Same Vial Over Four Weeks?+

Minimize vial access frequency by calculating total volume needed and drawing multiple doses at once into sterile syringes, then refrigerating the pre-loaded syringes separately. Each needle puncture introduces atmospheric oxygen into the vial headspace and risks microbial contamination despite preservatives. After 8–10 needle entries, even preserved solutions show measurable bacterial colony counts. For four-week protocols, consider splitting the reconstituted volume into weekly aliquots immediately after mixing. Four vials accessed once per week each outperform one vial accessed 12–16 times. If single-vial access is unavoidable, overlay the solution headspace with nitrogen gas after each draw and use the smallest-gauge needle practical (27G or 30G) to minimize headspace displacement.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Study Design Standards: Exclusion Criteria and Washout Protocols

The standard exclusion criterion in peptide research is self-reported cannabis use within 30 days of enrollment. This fails on two fronts: self-reporting is notoriously unreliable, and 30 days is insufficient for heavy users whose adipose-stored THC metabolites can remain detectable for 60–90 days post-cessation. A rigorous BPC-157 research cannabis consideration protocol requires quantitative metabolite screening at baseline using liquid chromatography-mass spectrometry (LC-MS) with a cutoff threshold of ≤2ng/mL 11-nor-9-carboxy-THC. The most persistent cannabis metabolite. Anything above that threshold indicates recent exposure that could affect receptor occupancy. For studies that do allow cannabis-exposed participants, a washout cohort is non-negotiable. This means enrolling subjects who test positive at baseline, documenting metabolite clearance over 8–12 weeks, and only initiating peptide administration once levels fall below the 2ng/mL cutoff. The advantage of this design is that you can compare within-subject outcomes before and after cannabinoid clearance, isolating peptide-specific effects without between-group confounding. The disadvantage is time and participant attrition. Fewer than 60% of enrolled participants complete a 12-week washout in our experience. But the alternative is publishing data that conflates two distinct biological mechanisms and contributing to a reproducibility crisis that's already plaguing peptide research. Baseline CB1/CB2 Saturation Minimal. Receptors available for peptide signaling Elevated. THC/CBD occupying 40–60% of available receptors Normalized. Metabolite clearance restores baseline receptor availability Post-washout cohorts provide cleanest data for isolating BPC-157 dose-response curves without receptor interference CYP3A4 Enzyme Activity Normal. Peptide clearance follows standard pharmacokinetics Inhibited. CBD reduces enzyme activity by 25–35%, prolonging peptide half-life Restored. Enzyme function normalizes within 4–6 weeks post-cessation Failure to account for enzyme inhibition skews dose-response data unpredictably across participants VEGF Pathway Baseline Standard. Peptide-induced angiogenesis measurable against tissue baseline Pre-elevated. Cannabinoid-mediated angiogenesis already active, compressing observable peptide effect Normalized. VEGF returns to tissue-specific baseline, peptide effect size increases Cannabis exposure reduces observable effect size by 15–25% in gastric repair endpoints. Post-washout groups show restored peptide sensitivity

RESEARCH

2. What does the preclinical evidence on BPC‑157 actually show?

Animal and cell‑culture studies report that BPC‑157 can influence tendon and ligament healing, gastrointestinal protection, and organ injury models, often with improvements in histological or functional endpoints compared with controls. These results are promising from a mechanistic standpoint but are limited to experimental systems and do not translate directly into proven clinical benefits.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

BPC-157 Research Models: Comparison

Gastric Ulcer Days to 50% closure + histological score 5–10 µg/kg Intraperitoneal 60–75% faster closure vs control Most consistent model. High reproducibility, strong effect size,…

Comparison

BPC-157 Research Caffeine Considerations: Protocol Comparison

Complete Avoidance No caffeine during active study period (typically 4–8 weeks) 100% baseline peptide efficacy preserved Withdrawal symptoms in habitual users; reduced cognitive p…

Comparison

BPC-157 Research Switching From Other Compounds: Comparison Table

TB-500 (Thymosin Beta-4) 20–24 hours 96 hours 7 days High. Both upregulate VEGF, promote angiogenesis, enhance fibroblast migration Requires longest washout due to persistent VEGF…

Continue reading

Related articles